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Abstract
Radiation therapy is an important modality in the treatment of lung cancer, but it can lead to radiation pneumonitis,
and eventually radiation fibrosis. To date, only few available drugs can effectively manage radiation-induced
pulmonary fibrosis. Lipoxins are endogenous molecules exhibit anti-inflammatory and pro-resolving effects. These
molecules play a vital role in reducing excessive tissue injury and chronic inflammation; however, their effects on
radiation-induced lung injury (RILI) are unknown. In this study, we investigated the effects of lipoxin A4 (LXA4) on RILI
using our specialized small-animal model of RILI following focal-ablative lung irradiation (IR). LXA4 significantly
inhibited immune-cell recruitment and reduced IR-induced expression of pro-inflammatory cytokines and fibrotic
proteins in the lung lesion sites. In addition, micro-CT revealed that LXA4 reduced IR-induced increases in lung
consolidation volume. The flexiVentTM assays showed that LXA4 significantly reversed IR-induced lung function
damage. Moreover, LXA4 downregulated the activities of NF-κB and the Smad-binding element promoters. The
expression of FPR2, an LXA4 receptor, increased during the development of IR-induced pulmonary fibrosis, whereas
silencing of endogenous LXA4 using an antagonist (WRW4) or FPR2 siRNA resulted in impaired development of
pulmonary fibrosis in response to IR. Collectively, these data suggest that LXA4 could serve as a potent therapeutic
agent for alleviating RILI.
Introduction
Radiation therapy is an important modality for treating
lung cancer. Generally, it is necessary to increase the
radiation dose to control the tumor by radiation, but
higher radiation dose results in higher probability of
developing side effects. Therefore, radiation-induced lung
damage (RILI) is a major bottleneck when aiming to
improve disease-free survival and well-being in patients
with lung cancer1–3. RILI is classified into two types, acute
phase radiation pneumonitis—that generally subsides
after a few weeks—and radiation-induced pulmonary
fibrosis that can develop several months or years after
irradiation (IR)4,5. Modern clinical radiotherapy techni-
ques, including stereotactic radiotherapy (SBRT)—which
delivers small fractions of ablative radiation doses—are
more accurate and precise than conventional radiotherapy
techniques. Previously, we had developed a mouse model
that simulates SBRT; we used an image-guided small-
animal IR system to deliver a single high dose of radiation
to the lung and verified the induction of pulmonary
fibrosis in response to IR6–8.
Radiation pneumonitis develops within hours or days of
lung IR and is accompanied by increased capillary per-
meability, leukocyte infiltration, and release of cytokines,
such as transforming growth factor β (TGF-β), interleukin
6 (IL-6), tumor necrosis factor alpha, and interleukin-1
beta (IL-1β). Subsequent alveolar lung inflammation and
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persistent inflammation may lead to symptomatic phases,
including pulmonary fibrosis9,10. TGF-β activation indu-
ces the differentiation of fibroblasts into myofibroblasts,
expression of α-smooth muscle actin (α-SMA), and
synthesis of extracellular matrix proteins, such as col-
lagen11,12. Alveolar epithelial cells (AECs) are another
important source of myofibroblasts and may differentiate
into myofibroblasts during idiopathic pulmonary fibrosis
and radiation-induced pulmonary fibrosis. This epithelial
or endothelial–mesenchymal transition (EMT or EndMT)
is generally known to be involved in the development of
pulmonary fibrosis13. During EMT, cells undergo a mor-
phological change from a round phenotype to a spindle-
like phenotype, accompanied by a loss of epithelial cell
markers—such as E-cadherin—and the gain of mesench-
ymal markers, such as vimentin and α-SMA14. In addi-
tion, NF-κB signaling—an important regulator of
inflammatory responses—and TGF-β/Smad signaling are
important regulatory mechanisms of EMT12,13,15.
The lipid mediator, LXA4, is a bioactive product of
arachidonic acid that has been reported to exert a variety
of activities in multiple tissues, including anti-
inflammatory effects, and regulation of neutrophil infil-
tration, pro-resolving signaling, macrophage polarization,
and the nonphlogistic uptake of apoptotic polymorpho-
nuclear neutrophils16,17. These activities of LXA4 are
regulated by the G protein-coupled ALX/FPR2 recep-
tor18,19. LXA4 reportedly reduces DM-related renal
fibrosis by targeting TGF-β/Smad signaling and sup-
presses liver fibrosis in experimental models by regulating
the immune responses and modulating the expression of
regeneration genes20,21. It also lowers TGF-β levels in
bleomycin-induced pulmonary fibrosis and exhibits an
anti-fibrotic effect22. Furthermore, lipoxin inhibits EMT
in cancer models, such as those of pancreatic and liver
cancers, and LXA4 was found to inhibit EMT in a renal
fibrosis model23–25. However, the role of lipoxin in RILI
has not yet been reported.
Here, we examined the anti-inflammatory and anti-
fibrotic properties of LXA4 using a mouse model of RILI,
wherein ablative radiation doses were delivered to the
focal lung area using an image-guided IR system6,7,26–28.
We also investigated whether LXA4 regulates proteins
that are important for EMT, particularly whether the
crosstalk between LXA4-ALX/FPR2 and TGF-β/Smad
signaling plays a key role in EMT.
Results
LXA4 inhibits radiation-induced lung inflammatory
responses
To mimic the effects of clinical radiotherapy in an
animal model of IR-induced lung damage, we had pre-
viously exposed mice lungs to high-dose radiation using a
small-animal micro-irradiator (X-RAD320) equipped with
a collimator system (to produce focal radiation
beams)7,8,28. These studies showed that radiation pneu-
monitis occurs in mice within 2 weeks of exposure to 60‒
100 Gy of IR8,15,28. Herein, we evaluated the effects of
LXA4 on pneumonitis 2 weeks after 75 Gy IR by evalu-
ating the lung morphology and performing hematoxylin
and eosin (H&E) staining and pulmonary function assays
(micro-computed tomography (CT) and flexiVentTM).
The normal lung was brown in color, whereas the irra-
diated lung exhibited a ring-like boundary with white-
colored adjacent areas 2 weeks post-IR (Fig. 1a, upper).
The IR group displayed significantly more inflammation
at the lesion site than the control group, and inflamma-
tion was significantly blocked by LXA4 (1.2 and 2 μg per
mouse) in the IR+ LXA4 group, which displayed less
damage than the IR group (Fig. 1b, left). Inflammatory
changes in the tissues surrounding the irradiated lesion
were also significantly reduced in the LXA4-treated
groups (1.2 and 2 μg/mouse) compared to those in the IR
group (Fig. 1b, right). Further, LXA4 significantly reduced
the IR-induced increases in the thickness of the bronch-
iolar epithelium and arterial wall (Fig. 1c). Micro-
computed tomographic (micro-CT) images taken
2 weeks after IR show that pulmonary consolidation
throughout the left lung of irradiated mice makes it
possible to measure high air-tissue contrast8,28. We found
that LXA4 reduced IR-induced pulmonary consolidation
(Fig. 1d, e); therefore, we analyzed pulmonary function—
based on six parameters—using the flexiVentTM system
(Supplementary Table 1). Four of these parameters
showed significant improvement in the IR+ LXA4 group,
i.e., IC (inspiratory capacity; IR vs. IR+ LXA4, 0.316 ±
0.0017mL vs. 0.3812 ± 0.0044 mL), Cst (quasi-static
compliance; IR vs. IR+ LXA4, 0.02428 ± 0.00048mL/
cmH2O vs. 0.03231 ± 0.0006852 mL/cmH2O), Rn (airway
construction; IR vs. IR+ LXA4, 0.4000 ± 0.04930 cmH2O/
mL vs. 0.2843 ± 0.01795 cmH2O/mL), and Rrs (central
airway resistance; IR vs. IR+ LXA4, 2.145 ±
0.1612 cmH2O/mL vs. 1.564 ± 0.1237 cmH2O/mL) (Fig.
1f).
Bronchoalveolar lavage fluid (BALF) differential cell
counts can provide supportive or even diagnostic infor-
mation regarding various conditions, including lung
inflammatory responses. IR increased the total number of
BALF cells compared to that in the control group,
whereas LXA4 rescued this effect and reduced the IR-
induced infiltration of immune cells such as CD163+ and
CD4+ cells (Fig. 2b). To confirm this anti-inflammatory
effect, we evaluated inflammatory cytokine and chemo-
kine expression, and found that while IR significantly
upregulated IL-1b, CCL2, and CCL8 expression, LXA4
attenuated their expression in the mouse model (Fig. 2c).
Similarly, LXA4 decreased the IR-induced increase in IL-
1b expression in MLE12 cells (Fig. 2d), and significantly
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attenuated IR-induced NF-κB promoter activity—which
mediates inflammatory gene transcription—in a dose-
dependent manner (Fig. 2e). However, WRW4—a specific
FPR2 antagonist—blocked the effect of endogenous LXA4
and enhanced IR-induced NF-κB promoter activity
(Fig. 2f).
LXA4 attenuates radiation-induced pulmonary fibrosis
Previously, we had observed that the inflammatory
response occurred for around 2 weeks, and that fibrosis
was apparent 4‒6 weeks after ablative doses of IR6,8,28.
Interestingly, we began to observe collagen deposition—
using Masson’s trichrome (MT) staining—2 weeks after
IR, with collagen deposition increasing thereafter (Fig. 3a).
This early fibrosis was attenuated by LXA4 as was the
expression of proteins involved in pulmonary fibrosis,
including IL-6, TGF-β, α-SMA, and Twist (Fig. 3b).
Moreover, LXA4 decreased IL-6, TGF-β, Col3a1, and
fibronectin (FN) mRNA levels, which were increased by
IR in MLE12 cells (Fig. 3c). Next, we performed a luci-
ferase reporter assay to determine whether the effect of
FPR2 on Smad-binding element (SBE) activity mediated
TGF-β/Smad signaling. IR increased SBE activity, whereas
LXA4 treatment significantly attenuated this increase (Fig.
Fig. 1 Effects of LXA4 on radiation-induced pneumonia 2 weeks after irradiation (IR). a Representative gross (top) and H&E (bottom) images of
left lung tissues 2 weeks after 75 Gy IR with or without LXA4 in the mouse model. Magnification, ×1.25, ×10, and ×40. b Quantification of
inflammatory foci at the lesion site (left) and in the surrounding lung tissue (right). c Quantification of bronchiolar epithelium (left) and arterial wall
(right) thickness in lung tissues. d 3-D micro-computed tomography (CT) of mouse lung tissue. Horizontal (top), trans-axial (middle), and 3-D images
(bottom) acquired 2 weeks post-IR. e Normal lung volume excluding consolidation was quantified using the micro-CT images. f Several mouse lung
function parameters were measured using the flexiVentTM system 2 weeks after irradiation, i.e., inspiratory capacity (IC), quasi-static compliance (Cst),
central airway resistance (Rn), and airway construction (Rrs). Data are expressed as the mean ± standard error (n= 3, *p < 0.05, **p < 0.01, and ***p <
0.001).
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3d, left). However, WRW4, a specific FPR2 antagonist,
blocked the effect of endogenous LXA4 and increased IR-
induced SBE-luciferase promoter activity (Fig. 3d, right).
Thus, LXA4 may regulate collagen deposition and protein
expression—associated with early RILI—and inhibit
inflammation after IR.
Six weeks after IR, LXA4 decreased the radiation-
induced increase in immune-cell infiltration and collagen
expression to match the levels in the early stage IR (Fig.
4a, b). Furthermore, we confirmed that WRW4, an FPR2
antagonist that blocks the effect of endogenous LXA4, was
upregulated in the IR-treated group (Fig. 4a, b). Bronch-
iolar epithelium thickness and arterial wall thickness also
responded to the inhibitory effects of LXA4 and WRW4
(data not shown). Moreover, the expression of α-SMA,
Twist, IL-6, and TGF-β was significantly inhibited by
LXA4 and increased by WRW4 (Fig. 4c). Lung function
was rescued by LXA4, which significantly reversed four of
the six lung function parameters (IC, Cst, Rrs, and Rn),
and was worsened by WRW4, but this was not significant
Fig. 2 Effects of LXA4 on radiation-induced inflammatory response. a Total BALF-cell count in mice 2 weeks post-IR. b Representative
immunohistochemical images of irradiated lung tissues using anti-CD163 and CD4 antibodies. Magnification, ×40. c IL-1b, CCL8, and CCL2 mRNA
expression in irradiated lung tissue measured using quantitative real-time PCR. d IL-1b mRNA expression in MLE12 cells measured using quantitative
real-time PCR. e pNF-κB reporter activity in MLE12 cells exposed to 6 Gy IR according to LXA4 dosage. f pNF-κB reporter fold activity in 6 Gy IR-
exposed MLE12 cells transfected with or without WRW4. Data are expressed as the mean ± standard error of three independent experiments (*p <
0.05, **p < 0.01, and ***p < 0.001).
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(Fig. 4d). These results demonstrate that LXA4 may
inhibit the development of radiation-induced fibrosis via
the FPR2 receptor.
Radiation affects LXA4-FPR2 signaling
Next, we explored whether IR affects LXA4 levels using
enzyme-linked immunosorbent assays (ELISA) on mouse
blood samples. As shown in Fig. 5a (left), endogenous
LXA4 levels were significantly lower 2 (12.56 ± 1.885 ng/
mL) and 6 (14.46 ± 2.248 ng/mL) weeks after IR than
those in the control group (18.33 ± 1.037 ng/mL). Simi-
larly, LXA4 levels in the human blood (Fig. 5a, right panel)
were significantly lower after 4 weeks of IR (5.527 ±
0.4614 ng/mL) than those in the control group (7.044 ±
0.2798 ng/mL). IR also reduced the lipoxygenase activity
in the mouse model and MLE12 cells (Fig. 5b) and
downregulated Alox12 (12-lipoxygenase) and Alox15 (15-
lipoxygenase), lipoxygenase variants—involved in
arachidonic acid metabolism—in mouse lung lesion sites
(Fig. 5c) and MLE12 cells (Fig. 5d).
To investigate FPR2 expression, we focally irradiated the
left lung of mice (3-mm diameter) with high-dose radia-
tion (75 Gy) at the indicated times. IR increased the
degree of pulmonary damage, as evidenced by
inflammatory-cell infiltration—H&E staining—and col-
lagen content—MT staining—in the IR-induced lung
damage model in mice (Supplementary Fig. 1). Moreover,
α-SMA expression—related to fibrosis—increased in the
irradiated left lung over time. Interestingly, IR sig-
nificantly increased FPR2 levels at the lesion site (Fig. 6a,
75 Gy; and Supplementary Fig. 2, 90 Gy) alongside FPR2
mRNA levels 2 weeks after IR; however, FPR2 mRNA
levels were lower 6 weeks after IR (Fig. 6b). We confirmed
IR-induced FPR2 expression in the mouse lung epithelial
cell line—MLE12—and in human endothelial cells
(HUVECs) using western blotting (Fig. 6c),
Fig. 3 LXA4 inhibits IR-induced pulmonary fibrosis at 2 weeks. a Representative MT-stained image of mouse lung tissue 2 weeks post-IR (75 Gy)
with or without LXA4 in the mouse model (left). Quantification of collagen content (right). Magnification, ×1.25, ×10, and ×40. b Representative
immunohistochemical image (left) and quantification (right) of irradiated lung tissues stained with antibodies against IL-6, TGF-β, α-SMA, and Twist.
Magnification, ×1.25 and ×40. c IL-6, TGF-β, Col3al, and fibronectin (FN) mRNA expression in the irradiated lung tissue of mice, measured using
quantitative real-time PCR. d pSmad reporter activity in 6 Gy IR-exposed MLE12 cells transfected with or without WRW4. Data are expressed as the
mean ± standard error of three to five independent experiments (*p < 0.05, **p < 0.01, and ***p < 0.001).
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immunofluorescence (Fig. 6d), and real-time quantitative
RT-PCR (Fig. 6e); these showed that FPR2 levels sig-
nificantly increased after 48 h of IR. Next, we performed a
luciferase reporter assay to determine the effect of FPR2
on SBE and NF-κB promoter activities, which regulate
TGF-β signaling and inflammatory responses. Interest-
ingly, IR increased the activities of both promoters in
MLE12 cells—as did si-FPR2—compared to those in
control (Fig. 6f). Therefore, these data suggest that the
altered LXA4 signaling, including increased FPR2
expression and crosstalk with TGF-β/Smad signaling, may
be involved in the development of IR-induced pulmonary
damage.
LXA4 blocks IR-induced cell death and oxidative response
IR increased the expression of the critical free radical
marker, 8-hydroxy-2′-deoxyguanosine (8-OHdG) over
time (Fig. 7a); therefore, we examined 8-OHdG levels and
NOX4 expression—which is involved in reactive oxygen
species (ROS) modulation—using immunohistochemistry
Fig. 4 LXA4 attenuates IR-induced pulmonary fibrosis and rescues lung function. a Representative gross (top), H&E (middle), and MT (bottom)
images of the left lung tissue 6 weeks after 75 Gy IR with or without LXA4 in the mouse model. Magnification, ×40. b Quantification of inflammatory
foci (left) and collagen content (right). c Quantification of relative α-SMA, Twist, IL-6, and TGF-β expression in the lung lesion site using
immunohistochemistry. d Functional measurement of several mouse lung parameters using the flexiVentTM system 6 weeks post-IR, i.e., inspiratory
capacity (IC), quasi-static compliance (Cst), central airway resistance (Rn), and airway construction (Rrs). Data are expressed as the mean ± standard
error (n= 3‒5, *p < 0.05, **p < 0.01, and ***p < 0.001).
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in irradiated mouse lung models to observe the effect of
LXA4 on radiation-induced oxidative stress. 8-OHdG and
NOX4 levels were increased 6 weeks post-IR, and were
significantly decreased by LXA4 (Fig. 7b). Moreover, LXA4
reduced IR-induced ROS production in MLE12 cells—
observed using a DCFDA probe (Fig. 7c)—and also
reduced MMP expression (Fig. 7d) and cell death (Fig. 7e).
These data suggest that LXA4 can block IR-induced
increase in cell death and oxidative response.
Discussion
As the use of radiation for treating cancer—and the
number of patients surviving cancer—is increasing
worldwide, it has become increasingly important to
improve the quality of life of these individuals and to
modulate the effects of radiation therapy on normal tis-
sues29. IR increases inflammatory reactions, thereby
causing inflammatory cells to accumulate in the lesion
sites of lung tissue, enhancing inflammatory cytokine
expression (IL-6, IL-1b, and TGF-β) in lung tissues, and
recruiting immune cells (macrophages, neutrophils, lym-
phocytes, and eosinophils) in BALF6,28. To our knowl-
edge, this study is the first to demonstrate the effect of
lipoxin on RILI; it reveals that LXA4 exhibits anti-
inflammatory and anti-fibrotic effects in a RILI model.
LXA4 not only inhibited radiation-induced pro-inflam-
matory cytokine production but also suppressed immune-
cell recruitment into the alveolar space, downregulated
fibrosis-related gene expression, and restored the
damaged lung tissue and function, thereby
ameliorating RILI.
Although lipoxins were discovered almost four decades
ago, they have not yet reached the clinical trials stage—as
potential drugs to treat inflammatory diseases—owing to
their short half-life and instability on exposure to acids
and light; however, stable analogs are being developed. In
this study, we predominantly investigated the anti-fibrotic
effects of LXA4—2 and 6 weeks after 75 Gy of IR—by
immunostaining for α-SMA, TGF-β, and Twist and by
MT staining for collagen expression. Two weeks after
exposure to 75 Gy IR, our experimental model manifested
radiation pneumonitis with radiation-induced inflamma-
tion, whereas 6 weeks after 75 Gy IR exposure, the model
manifested IR-induced lung fibrosis with increased
fibrosis marker and collagen expression8,26,28. To inves-
tigate the crosstalk between FPR2, IR-induced
Fig. 5 IR reduces LXA4 production. a Determination of plasma LXA4 concentration in mice. Plasma samples were collected from mice 2 and
6 weeks post-75 Gy IR and their LXA4 levels were measured by ELISA. b LOX enzyme activity was measured in mice (left) and MLE12 cells (right) using
a Lipoxygenase Assay kit, according to the manufacturer’s instructions. ALOX12 and ALOX15 mRNA levels in the irradiated lung tissues of mice (c)
and MLE12 cells (d) measured using quantitative real-time PCR. Data are expressed as the mean ± standard error (n= 3‒5, *p < 0.05, **p < 0.01, and
***p < 0.001).
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inflammatory responses, and fibrosis-related gene
expression, we observed NF-κB and SBE promoter activity
in the background of IR. NF-κB regulates inflammation-
related signals, and its activity is known to increase during
various inflammatory reactions, including radiation. We
confirmed that IR increased NF-κB and SBE promoter
activities in TGF-β/Smad signaling, which regulates the
expression of fibrotic genes. In addition, administering si-
FPR2 and WRW4 to reduce the effects of endogenous
FPR2 further increased the activities of these two pro-
moters in the IR group, whereas LXA4 suppressed their
activities. To investigate the effects of LXA4 against IR-
induced fibrosis, we performed a variety of assays.
Immunohistochemistry for 8-OHdG and NOX4 revealed
that LXA4 inhibited oxidative stress, suggesting that LXA4
may have antioxidant properties. IR-mediated ROS are
known to induce apoptosis in lung epithelial cells30, which
can cause pulmonary fibrosis;31 although inhibition of
AEC apoptosis has been shown to attenuate fibrosis32, it
did not affect IR-induced cancer cell death in A549 cells
(Supplementary Fig. 4).
Chest CT and studies on pulmonary function are
important factors to consider when clinically evaluating
respiratory diseases. micro-CT is often used in preclinical
studies to measure lung injury as it allow the therapeutic
effects of drugs to be evaluated quickly and noninvasively.
FlexiVentTM is a system—with a pre-programmed venti-
lator—that directly evaluates lung function based on the
functional parameters used in humans33. Here, LXA4-
treated mice displayed significantly better micro-CT
finding and flexiVentTM lung function values than sim-
ply irradiated mice. Moreover, these results correlated
Fig. 6 IR regulates ALX/FPR2 expression. a Representative image (top) and quantification (bottom) of irradiated lung tissues (75 Gy) stained for
FPR2 and α-SMA at the indicated times. Magnification, ×1.25 and ×40. b FPR2 mRNA levels in IR-exposed mouse lung tissue measured using
quantitative real-time PCR. c FPR2 expression measured by western blotting after exposure of MLE12 cells and HUVECs to 6 Gy IR. d FPR2 expression
24 h after 3 and 6 Gy IR in MLE12 cells and HUVECs; FPR2 (green); DAPI (blue). e FPR2 mRNA levels in MLE12 cells and HUVECs exposed to 6 Gy IR,
measured using quantitative real-time PCR. f pSmad and pNF-κB promoter reporter activity in 6 Gy IR MLE12 cells transfected with or without
FPR2 siRNA. Data are expressed as the mean ± standard error (n= 3‒5, *p < 0.05, **p < 0.01, and ***p < 0.001).
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with the histopathological findings—H&E and MT stain-
ing—suggesting that LXA4 can prevent IR-induced lung
function deterioration.
LXA4 is reportedly involved in airway inflammation; its
levels decrease in chronic airway inflammatory diseases,
such as asthma, chronic obstructive pulmonary disease,
and cystic fibrosis34,35. Moreover, a reduced proportion of
pro-resolving compounds (LXA4)—compared to pro-
inflammatory compounds (LTB4)—is associated with
decreased lung function36. LXA4 is generated during the
interaction of lipoxygenases (LOXs) via trans-cellular
cooperation in several immune cells, including neu-
trophils, eosinophils, alveolar macrophages, and platelet
airway epithelial cells37–39. Here, IR decreased LXA4
production—in the mouse model and in human blood
samples—LOX activity and expression of ALOX12 and
ALOX15. Conversely, IR increased the expression of the
LXA4 receptor FPR2 in the mouse lung tissue model and
in MLE12 cells and HUVECs. Further studies should
investigate FPR2-LXA4 interactions in lung cells at dif-
ferent time points after IR, in addition to investigating the
effect of LXA4 on aspects of radiation-induced inflam-
mation, such as inflammasome activation and immune-
cell infiltration, which promote immune resolution.
Consistent with our findings, LXA4 signaling has
recently emerged as an endogenous anti-inflammation
and anti-fibrosis pathway40–42; however, natural LXA4 has
low biological efficacy owing to its instability. To
Fig. 7 LXA4 decreases the IR-induced oxidative response. a Representative image (right) and quantification (left) of irradiated lung tissues stained
with antibodies against 8-OHdG at the indicated times. Magnification, ×1.25 and ×40. b Quantification of relative 8-OHdG and NOX4 expression in
the lung lesion site 6 weeks after 75 Gy IR with or without LXA4 using immunohistochemistry. c ROS levels were measured by incubating irradiated
MLE12 cells treated with or without LXA4 with a DCFDA probe. d MMP3, MMP8, and MMP12 mRNA expression in IR-exposed mouse lung tissue,
measured using quantitative real-time PCR. e Colony forming activity was examined in MLE12 cells. Data are expressed as the mean ± standard error
(n= 3, *p < 0.05, **p < 0.01, and ***p < 0.001).
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overcome these limitations, many researchers have
developed analogs—that mimic the core structure of
native LXA4—as potential drugs
43,22. Therefore, it may be
beneficial to introduce and develop these analogs in our
radiation-induced lung damage model to maximize the
anti-inflammation and anti-fibrotic effects of LXA4.
In conclusion, although the precise mechanisms
underlying radiation-induced lung fibrosis remain
unclear, we demonstrated that LXA4 exerts protective
effects by inhibiting collagen production, decreasing the
expression of fibrosis-related proteins and inflammatory
cytokines, and blocking NF-κB and TGF-β/Smad signal-
ing. Collectively, these results suggest that LXA4 reduces
radiation-induced lung inflammation and fibrosis and
may therefore serve as a useful therapeutic agent for
inhibiting radiotherapy-induced inflammatory responses
and fibrosis in normal lung tissue.
Materials and methods
Animal experiments and LXA4 administration
All protocols involving the use of mice were approved
by the Animal Care and Use Committees of Yonsei Uni-
versity Medical School, Seoul, South Korea (YUHS-
IACUC; 2016-0199), and were performed in accordance
with the relevant guidelines. Male C57BL/6 mice (age,
6 weeks; weight, 20–25 g) were purchased from Charles
River Korea (Orient Bio, Seongnam, South Korea) and
allowed to acclimatize (n= 5 per cage) for a week before
IR. A single dose of 75 Gy IR was delivered to the left lung
using an image-guided small-animal irradiator (X-RAD
320; Precision, North Branford, CT, USA) equipped with
a collimator comprising 3.5-cm-thick copper—for pro-
ducing focal radiation beams—and an imaging subsystem
comprising a fluorescent screen coupled to a charge-
coupled-device camera. In all experiments, 3-mm colli-
mators were used to mimic clinical SBRT conditions with
a small IR volume in lung tissues. The mice were ran-
domly divided into the following three groups (n= 3‒5
per group): (1) control group; (2) IR group exposed to a
single dose of 75 Gy delivered to the left lung in a single
fraction; (3) IR+ LXA4 group treated intravenously with
LXA4 (0.4, 1.2, or 2 µg/ mouse) 2 weeks after IR. The mice
were euthanized by CO2 inhalation, and their lung tissues
were collected for analysis. LXA4 levels were measured in
serum samples using an LXA4 ELISA kit (Cusabio Bio-
tech, Wuhan, China) according to the manufacturer’s
protocol.
Human blood specimens
The collection of blood samples from patients with lung
cancer was approved by the Ethics Committee of Sever-
ance Hospital, Yonsei University, Seoul, South Korea (4-
2014-0193). After informed consent, 10-mL blood sam-
ples were collected from each patient before radiotherapy
to determine LXA4 levels in the serum, at the 2nd and 4th
week after definitive radiotherapy for curative aim. The
samples were centrifuged, and the serum was frozen and
stored at −70 °C until further analysis. LXA4 levels were
measured in serum samples using an LXA4 ELISA kit, as
described above.
Cell culture
HUVECs were kindly provided by Dr. Yoon-Jin Lee
(Division of Radiation Effects, Korea Institute of Radi-
ological and Medical Sciences, Seoul, Korea) and were
grown in Endothelial Growth Medium-2 (EGM-2; Pro-
mocell GmbH, Heidelberg, Germany) in 0.1% gelatin-
coated dishes at 37 °C in a humidified atmosphere con-
taining 5% (v/v) CO2. The mouse lung epithelial cell line,
MLE12, obtained from the American Type Culture Col-
lection, was grown in Dulbecco’s modified Eagle’s med-
ium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/mL penicillin, and 100mg/mL streptomycin
at 37 °C in a humidified atmosphere containing 5% (v/v)
CO2. The cells were seeded (density, 1.0 × 10
6 cells) in a
60-mm plate. After 24 h, the cells were washed and
maintained in serum-free medium before the
experiments.
Preparation and histological evaluation of lung tissue
sections
Tissues from the left lung of the irradiated mice were
fixed in 4% paraformaldehyde for 24 h, dehydrated, and
embedded in paraffin. Tissue sections were stained with
H&E, MT, and TGF-β, α-SMA, 8-OHdG, and IL-6 anti-
bodies (Abcam, Cambridge, MA, USA).
Immunohistochemistry and immunofluorescence
To detect TGF-β, α-SMA, 8-OHdG, and IL-6, tissue
sections were probed with primary antibodies (4 °C
overnight), followed by incubation with the avidin–biotin
peroxidase complex (ABC Kit, Vector Laboratories, CA,
USA), and were developed using 3, 3′-diaminobenzidine
tetrachloride (DAB; Zymed Laboratories, CA, USA). For
immunofluorescence, tissues were probed overnight with
primary antibodies diluted in phosphate buffered saline
(PBS) containing 0.5% bovine serum albumin (BSA) and
then incubated overnight with fluorescent-conjugated
secondary antibodies (Vector Laboratories, CA, USA)—
diluted in the same buffer as the primary antibodies—at
4 °C. These sections were mounted on a gelatin-coated
slide using a fluorescent mounting medium (Dako,
Glostrup, Denmark) and dried.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde—in PBS—
permeabilized with 0.1% Triton X-100 for 10 min at room
temperature, and washed several times with PBS. The
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cells were then incubated with pSmad2/3 primary anti-
bodies (Abcam, Cambridge, MA, USA) at 4 °C overnight,
blocked with 1% BSA in PBS, and stained with secondary
Texas Red-conjugated antibodies. Next, the cells were
stained with DAPI, mounted on coverslips, and observed
under a confocal microscope.
Western blotting
Cells were lysed with RIPA buffer (50 mM Tris-HCl, pH
7.4; 1% Nonidet P-40; 0.25% sodium deoxycholate;
150mM NaCl; 1 mM Na3VO4) containing protease inhi-
bitors (2 mM phenylmethylsulfonyl fluoride; 100 μg/mL
leupeptin; 10 μg/mL pepstatin, 1 μg/mL aprotinin; 2 mM
EDTA) and a phosphatase inhibitor cocktail (GenDEPOT,
Baker, TX, USA). After incubation for 20min at 4 °C, the
lysates were centrifuged at 13,000 rpm for 20min at 4 °C,
and the supernatants were collected for western blotting.
Protein concentration was measured using a BCA protein
kit (Bio-Rad, Hercules, USA). The lysates were subjected
to SDS-PAGE gel electrophoresis, transferred onto poly-
vinylidene fluoride membranes (Millipore, Bedford, MA,
USA), and incubated with 5% skimmed milk for 1 h at
room temperature. The membranes were then probed
with primary antibodies against α-SMA (Abcam, Cam-
bridge, MA, USA), FPR2 (Novus Biological, Littleton, CO,
USA), and actin (Santa Cruz Biotechnology, Dallas, TX,
USA), followed by incubation with horseradish
peroxidase-coupled secondary antibodies (Jackson
Immunoresearch, West Grove, PA, USA). Proteins were
detected using ECL Plus western blotting detection
reagents (Amersham Biosciences, Piscataway, NJ, USA).
micro-CT analysis
Micro-CT images were acquired using a volumetric CT
scanner (NFR-Polaris-G90MVC: NanoFocusRay, Iksan,
South Korea) and reconstructed using volumetric cone-
beam reconstruction (Feldkamp–Davis–Kress method) in
online/offline modes. Volumetric analysis was performed
using ImageJ software (http://imagej.nih.gov/ij/). To
minimize inter-specimen measurement variation, the
same settings were used to analyze all images.
Functional lung assessment
Lung function in irradiated mice was evaluated using a
flexiVentTM system (SCIREQ, Montreal, QC, Canada),
which measures flow-volume relationships in the respiratory
system—including forced oscillation—to discriminate
between airway and lung tissue variables27. This system was
used according to the manufacturer’s instructions.
Transfection and reporter gene assay
Transient transfection was performed using Effectene
(Qiagen; Santa Clara, CA, USA) according to the
manufacturer’s protocol. Briefly, 1.0 × 106 cells were
seeded in a 60-mm dish a day before transfection and
grown to ~70% confluence. The cells were then trans-
fected with 0.1 µg of plasmid DNA—SBE-luc from the
SBE Reporter Kit (BPS Bioscience, CA, USA)—or the
NF-κB-luc vector pGL4.32 [luc2P/ NF-κB-RE/Hygro]
(Promega, Madison, WI, USA) along with 10 nM siRNA
against FPR2 (si-FPR2) or control siRNA. The next day,
the transfected cells were treated with or without
radiation (6 Gy) for 48 h and harvested for protein
extraction, real-time-qPCR, or further analysis. All
experiments were performed in triplicate, and repre-
sentative results were reported. For the reporter assay,
cells were lysed and assayed for luciferase activity
according to the manufacturer’s instructions (Promega,
Southampton, UK).
Quantitative real-time polymerase chain reaction (qRT-
PCR)
Total RNA was isolated from cells using TRIzol (Invi-
trogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions, and cDNA was synthesized using a
Quantifect Reverse Transcription Kit (Qiagen, Hilden,
Germany). qRT-PCR was performed using SYBR Premix
Ex Taq (Takara, Hercules, CA, USA), primers, RNase-free
H2O, and cDNA (final reaction volume, 20 µL) under the
following cycling conditions: 95 °C (10 min); and 50 cycles
of 95 °C, (20 s), 55 °C (30 s), and 72 °C (20 s). The mouse
primer sequences are available in the Supplementary
Table 2. All experiments were performed in triplicate, and
the results were normalized to glyceraldehyde 3-
phosphate dehydrogenase expression. mRNA expression
was calculated using the delta Ct method.
Luciferase reporter assay
MLE12 cells were cultured in 60-mm plates using
complete medium until they reached ~70% confluency,
and were then co-transfected with either SBE-luciferase
+TK-Renilla luciferase or NF-κB-luciferase+TK-Renilla
luciferase. After 24 h, the cells were irradiated using an
image-guided small-animal irradiator, and the ratio of
firefly/Renilla luciferase was calculated and normalized to
untreated controls. Luciferase activity was measured using
luciferase assay reagents (Promega Corp., Madison,
Wi, USA).
Colony formation assay
A549 and MLE12 cells were cultured in 35-mm dishes
using DMEM supplemented with 10% FBS in the back-
ground of IR (5 Gy) using an X-rad320 (Precision, North
Branford, CT, USA). After 2 weeks—with or without
LXA4 treatment—the cells were fixed, stained with 0.5%
crystal violet, and quantified for colony number.
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Statistical analysis
Statistical analysis was performed using GraphPad
Prism 5 (GraphPad Software, La Jolla, CA, USA). Differ-
ences between the means of two groups were evaluated
using Student’s t tests. Differences between the means of
multiple groups were evaluated by one-way analysis of
variance. The threshold for significance was p < 0.05, and
all values were expressed as the mean ± SEM.
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